ALGS (aligos.com) Net Profit

Official company branding of Aligos Therapeutics, Inc. (ALGS)

Diversification of hepatology programs protects Aligos Therapeutics (ALGS) from the risks of clinical trial failures. Negative cash flow is currently offset by balance sheet liquidity. The company's net profit trend demonstrates financial stability, where -0.08 forms the current metric value. Business revenues will be based on the commercialization of innovative treatments for non-alcoholic steatohepatitis and hepatitis B following their registration.

ALGS (Aligos Therapeutics Inc.) Company Net Income history from 07/04/2022 to 10/30/2026

Comprehensive metric breakdowns and analytics for aligos.com (ALGS)

- price and consensus price forecast:
Stock Quotes Aligos Therapeutics, Inc.|ALGS - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Aligos Therapeutics, Inc.|ALGS - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Aligos Therapeutics|ALGS - Company Book Value|Market Value to Book Value Ratio aligos.com|ALGS - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient Aligos Therapeutics|ALGS - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Aligos Therapeutics, Inc.|ALGS - Company Aggregate Debts|Debts to Book Value Aligos Therapeutics, Inc.|ALGS - Company Long-Term Debt|Company Short-Term Loans and Borrowings Aligos Therapeutics|Quick Ratio aligos.com
- net income and valuation multiples indicators:
ALGS - Company Net Income
Fundamental valuation:ALGS Aligos
Mass-produced product of Aligos Therapeutics, Inc.

Aligos Therapeutics (ALGS) net income measures the daily economic outcome of the business, neutralizing quarterly reporting lags to reveal the actual dynamics of operating income. By analyzing the Aligos Therapeutics (ALGS) net income chart, an investor can assess the company's viability amidst a strict duopoly in the liver therapy market and the risks posed by universal vaccines, separating the asset's fundamental value from speculative market expectations.

Main competitors

Net Income Arrowhead Corp|MIRM (Mirum Pharmaceuticals) - Net Profit|Net Profit Dynavax Corp|Net Income ABUS (Arbutus Biopharma Corporation)|IVA (Inventiva SA) - Final Profit|Company Net Income Gyre Corp GYRE|Assembly Corp - Company Net Income|Galectin - Net Profit|Net Financial Result Genfit S.A. GNFT|DRRX (durect.com) - Net Income|BIVI (BioVie) - Company Net Income|GLMD (Galmed Pharmaceuticals Ltd) - Net Profit|Company Net Income ENDRA Corp NDRA|Company Net Income Hepion Pharmaceuticals (HEPA)